COMP <GO>

MNPR vs EPRX // 10Y YIELD & FRED MACRO BETA

Monopar Therapeutics Inc. (NASDAQ) VS. Eupraxia Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: MNPR 4 — EPRX 1

■ METRIC PARITY

LAST: $71.91 (-2.02%) • MKT CAP: $482.7M

macro-sensitivity

—

LAST: $7.25 (-1.76%) • MKT CAP: $477.8M

macro-sensitivity

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MNPR VS. EPRX) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	MNPR	EPRX	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-17.40%	-35.00%	+17.60	MNPR	/roic <GO>
EV/EBITDA & P/E Valuation	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	-2.53%	-5.98%	+3.45	MNPR	/fcf-yield <GO>
Operating Margin	—	—	—	TIE	/operating-margins <GO>
Net Profit Margin	—	—	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	—	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	—	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	3/9	2/9	+1.00	MNPR	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	33.4	43.2	-9.75	EPRX	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$482.7M	$477.8M	$4.8M	MNPR	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	MNPR REV	EPRX REV	MNPR GROSS %	EPRX GROSS %	MNPR FCF	EPRX FCF
FY 2025	$0	$0	—	—	-$12.2M	-$28.6M
FY 2024	$0	$0	—	—	-$6.4M	-$30.0M
FY 2023	$0	$0	—	—	-$7.9M	-$20.7M

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

MNPR // BETA —

EPRX // BETA —